The global COVID-19 vaccines-production capacity & development timeline market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. In early months of 2021, many companies had entered phase II trials of several vaccines across the globe and were ready to launch them for the public use. Rising investment from various research groups and their unparalleled research efforts with respect to scale and speed up the development of drugs are projected to expand the market. The COVID-19 vaccine development is growing faster than other vaccines development as other vaccines needed general time slot about 20 years. For instance, the development of Human Papilloma Virus (HPV) vaccine took about 26 years while the development of the Respiratory Syncytial Virus (RSV) vaccine took more than 50 years.
World Health Organization (WHO) and the government regulatory bodies had taken various initiatives for early research and vaccine development. The Coalition for Epidemic Preparedness Innovations (CEPI) and WHO have conducted the COVAX vaccine initiative for rapid development and rising access to contributing economy. These bodies also jointly working for enhancement of manufacturing capacity and proficient management of the buyer-supplier chain, to enable correct distribution of more than 2 billion doses by the end of 2021. Till August 2020, around 170 countries were present for the discussion of potential participation in COVAX.
As COVID-19 vaccine is considered to be a non-profit making market, therefore funding from governments is a major concern. Biomedical Advanced Research and Development Authority (BARDA) guided small companies for their benefits. BARDA helps in simplification of communication between regulatory agencies and provides guidance for trial design and expectations of regulatory agencies. Sanofi entered into a partnership with BARDA and GSK for its traditional vaccine, which was based on the further development of baculovirus expression system. Based on manufacturer’s and payer’s perspective, the Quality Adjusted Life Year (QALY) and Case Fatality Ratio (CFR) are also considered and vaccine pricing is set differently than other drugs pricing. The pricing depends on incidence of COVID-19, which motivate immunologists for rising focus on infection and development of exciting platforms.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing vaccine product supply to meet the enormous demand across the globe is one of the major factor responsible for driving the market growth.
- Rising government funding, increasing company investments, and quicker regulatory approvals are expected to fuel the market growth during the forecast period.
- Growing initiatives from regulatory bodies, arrival of next-generation vaccine platforms, and growing number of COVID-19 patients are anticipated to boost the market expansion in coming years.
- High cost operation related with R&D activities and long timeline for the development of therapeutic drugs and vaccines, required complex steps for the approval of every phase of clinical trials are estimated to impede the growth of the market.
- Stringent regulation and high cost associated with per dose vaccine are major factors to restrict the market growth during the forecast period.
Scope of the Report
The report on the global COVID-19 vaccines-production capacity & development timeline market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
COVID-19 Vaccines-Production Capacity & Development Timeline Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types (Virus-like Particle, Whole Virus, Protein, Antibodies, Viral Vector, and mRNA/DNA)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland.
|
Market Segment Insights
Protein segment is projected to hold a major market share
Based on types, the COVID-19 vaccines-production capacity & development timeline market is segmented into virus-like particle (VLP), whole virus, protein, antibodies, viral vector, and mRNA/DNA. The protein segment is expected to hold a key share of the market during the forecast period. This type of vaccine consists of purified pieces of pathogen to trigger the immune response. Owing to appearance of significant positive effects, the adoption of these vaccines are constantly increasing during the recent months.
On the other hand, the viral vector segment is anticipated to expand at a rapid pace during the forecast period owing to presence of manufacturing infrastructure that helps the development of effective vaccine in lesser time period. The whole virus type vaccine is used as deactivated and weakened pathogens, which triggers protective immunity. Inactivated pathogens are used by Sinopharm and Sinovac. The VLP vaccines consist of inactivated and weakened viruses. The protein-based vaccines are dominating the market for clinical trials. Many researchers and developers are focusing on evaluating and monitoring spike (S) protein.
North America is expected to dominate the market
On the basis of regions, the COVID-19 vaccines-production capacity & development timeline market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to presence of multiple private organizations and academic institutes for developing vaccines. In the U.S., the Operation Warp Speed (OWS) is a key national program for various strategies related to vaccine development, therapeutics, and detection of coronavirus.
Segments
Segments Covered in the Report
The global COVID-19 vaccines-production capacity & development timeline market has been segmented on the basis of
Types
- Virus-like Particle
- Whole Virus
- Protein
- Antibodies
- Viral Vector
- mRNA/DNA
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer
- Moderna
- BioNtech
- Sanofi
- Zydus Cadila
- CureVac
- Imperial College London
- Takara Bio
- CanSino Biologics
- Beth Israel Deaconess Medical Center
- ReiThera
- Novartis
- Anhui Zhifei Longcom
- Novavax
- University of Queensland
Competitive Landscape
Key players competing in the COVID-19 vaccines-production capacity & development timeline market include Pfizer, Moderna, BioNtech, Sanofi, Zydus Cadila, CureVac, Imperial College London, Takara Bio, CanSino Biologics, Beth Israel Deaconess Medical Center, ReiThera, Novartis, Anhui Zhifei Longcom, Novavax, and the University of Queensland.
Many of these market players are looking at opportunities to implement business strategies such as mergers, acquisitions, partnerships, capacity expansion, and product launches to enhance their market shares. Companies are also adopting collaboration strategy for the best result and early launch of vaccines. For instance, Moderna collaborated with Lonza, AstraZeneca with Serum Institute of India and Pfizer, and BioNTech with Pfizer to expand their product portfolio.
Request For Customization
Enquiry Before Buying
Speak With Analyst
